RxDoctor Payments Data

Louise Gautreaux, MD

Obstetrics & Gynecology · Kenner, LANPI 1962442285

Payments from drug & device makers

$1,532in general payments, 2019–2025

Across 76 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$445
  • AbbVie$267
  • Asensus Surgical, Inc.$100
  • Mayne Pharma Commercial LLC$93
  • Hologic Sales And Service, LLC$90
  • Millicent US Inc$76
  • plus $461 from 14 others

What the payments were for

  • Food & beverage$1,26883%
  • Education$26417%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,532 in reported general payments places this provider in the 60th percentile of 608 obstetrics & gynecology providers in Louisiana.

See all obstetrics & gynecology providers in Louisiana

Medicare billing

Part B allowed, 2024
$8,351
Medicare patients
59
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron22$15,826
MyrbetriqMirabegron19$12,871
VeozahFezolinetant15$8,358
PremarinEstrogens, Conjugated22$6,276
Estradiol203$5,783
Estradiol (Twice Weekly)Estradiol22$1,973
ValacyclovirValacyclovir Hcl25$1,706
Ibandronate Sodium32$1,381
Tolterodine Tartrate ErTolterodine Tartrate11$1,151
Clobetasol Propionate35$789
Medroxyprogesterone Acetate63$730
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip38$620
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$368
Fluconazole33$275
Venlafaxine Hcl ErVenlafaxine Hcl13$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Veozah$445$21,22934 claims
Sumitomo Pharma America, Inc.Gemtesa$51$15,82622 claims
PfizerPremarin$41$6,27622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 608 obstetrics & gynecology providers in Louisiana.

Other obstetrics & gynecology in Kenner

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →